Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Author(s):: Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Carinelli, S.; Provencher, D.; Hanzen, C.; Lutgens, L.C.H.W.; Smit, V.T.H.B.M.; Singh, N.; ; D'Amico, R.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. (0000-0002-7008-4321); PORTEC Study Grp

Date issued: 2018-03-31
Language: English
Is part of: The Lancet Oncology (2018), Vol. 19, no. 3, p. 295-309
hdl: 1887/74981
doi: 10.1016/S1470-2045(18)30079-2
URL: https://www.sciencedirect.com/science/article/pii/S1470204518300792?via=ihub